Olympus Launches Intelligent OLYSENSE Endoscopy Portfolio to Advance GI Diagnostics

Published: 03 Oct 2025

Author: Precedence Research

Share :

Olympus Corporation, a global MedTech leader dedicated to advancing patient health and safety. This has officially launched its OLYSENSE CAD/AI portfolio in both the United States and Europe. The recent surge in cloud-based, artificial intelligence applications marks a significant step toward developing an intelligent endoscopy ecosystem. OLYSENSE will enable physicians and simplify the workflow and enhance the outcome of gastrointestinal (GI) care through the integration of advanced detection and real-time clinical support.

The launch comes at a critical juncture for healthcare systems worldwide. As the need to perform endoscopic procedures increases due to aging populations and rising cases of gastrointestinal infections. Clinicians are increasingly challenged by the increasing demands of patients and the scarcity of resources and workforce. The new platform by Olympus is a direct response to these pressures, proposing AI-based solutions that minimize subjectivity and enhance the accuracy of diagnosis. This reduces the time required to process information, which ultimately enables more patients to receive earlier interventions and more effective treatments.

The launch of OLYSENSE also demonstrates that Olympus is aware of the current situation among gastroenterologists. Administrative burdens and constrained budgets, combined with clinical complexities, necessitate that physicians be equipped with technologies not only to identify abnormalities but also to reduce workloads and support clinical decisions. OLYSENSE reduces the risk of oversight by automating the detection process and standardizing the evaluations, providing physicians with confidence in their decision-making. 
The impact is not limited to patients, as healthcare providers will experience reduced variability, improved efficiency, and potentially lower costs, which can be applied to system-wide savings. In the future, Olympus has assured that OLYSENSE will continue to grow, with additional modules and AI applications that cater to new GI conditions and beyond. By scaling solutions by solution, the company plans to develop its smart ecosystem and respond dynamically to the needs of clinicians worldwide.

Executive’s Statement

Stefan Kaufmann, CEO of Olympus Corporation, stated:

"With OLYSENSE, Olympus is not only delivering a breakthrough in endoscopic care but also redefining what it means to integrate AI into clinical practice. Our mission is to help physicians see more, decide faster, and treat earlier, ultimately giving patients the best possible outcomes."